Mechanism of action of both magnesium and zinc in mediating their antidepressant activities is supposed to be through NMDA receptor antagonism. In the background of similarity in mechanism of action of zinc and magnesium as antidepressant through antagonism of NMDA receptors and evidences for anticonvulsant actions of magnesium being mediated through NMDA receptors blockade; present study was designed to test whether zinc has an additional anticonvulsant activity. Thirty six albino rats of either sex were divided in to 6 groups with 6 animals in each group. Group-I received distilled water (1ml/kg body weight) was control group. Group-II receiving phenytoin sodium (20mg/kg body weight) was the standard group. Group-III, IV and V were test groups receiving zinc sulfate at doses of 30mg/kg, 150mg/kg and 300mg/kg respectively. Animals were screened for anticonvulsant activity by Maximum Electroshock (MES) method and for generalized CNS depressant effect by photo-actometer method. With regard to anticonvulsant activity there was no statistically significant differences between any of the zinc sulfate treated groups with control and standard drug phenytoin. There was no evidence for possible anticonvulsant activity of zinc after single dose treatment at three selected doses in presence of generalized CNS depressant effect.
Incidence of obesity continues to rise worldwide with each year especially in developed countries. On the other hand success achieved with pharmacotherapy of obesity is disappointing, with some of the unmet needs in management strategies for obesity. Zonisamide an anti-epileptic drug has been found to have significant weight reduction properties with favorable safety profile. Present meta-analysis has been done with the aim of analyzing the efficacy of zonisamide in obesity. Electronic data bases were searched for all types of studies related to use of zonisamide in obesity and binge eating disorder. Change in body weight following treatment with zonisamide was the primary outcome measure analyzed. Both fixed and random effect models were used for statistical analysis of the data. With total 111 patients analyzed from 3 eligible studies; a significant reduction in weight from baseline by 5.88 kg (MD: -5.88; 95% CI:-7.51 to -4.25) at 16 weeks could be expected by treatment with zonisamide. As the data on safety profile of zonisamide especially long term was either incomplete or not available, analysis of safety profile was not carried out. Future studies analyzing the efficacy and long term safety of zonisamide on large population and for long term are preferred.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.